Why SYLVANT
About SYLVANT
Why SYLVANT?
The one and only FDA-approved treatment for people with idiopathic multicentric Castleman disease (iMCD) since April 2014
SYLVANT continues to be the cornerstone for iMCD treatment
Siltuximab is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred first-line treatment option for iMCD
NCCN Guidelines® are important because they help doctors choose the right treatments.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Castleman Disease V.1.2024.
© National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed April 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
My doctor said he could give me a drug that would target interleukin-6 (IL-6). Siltuximab (SYLVANT) does this.
How SYLVANT Works
SYLVANT targets and binds to IL-6, a driver behind iMCD:
Binds to IL-6:
SYLVANT binds to the IL-6 cytokine, preventing it from binding to its receptor
Blocks signaling:
This binding blocks the overactive immune system response that IL-6 normally triggers
Calms cytokine storm:
Thereby reducing iMCD symptoms caused by the cytokine storm
IL-6
Cytokines
Immune cells
IL-6 receptor
Cytokine storm
SYLVANT
By binding to IL-6, SYLVANT may lower the level of free IL-6 in the body and lessen the cytokine storm that may cause some iMCD symptoms.
While taking SYLVANT, your blood tests may show high IL-6 levels because standard tests cannot tell the difference between free IL-6 and IL-6 that is bound to SYLVANT.
Find out how people responded to SYLVANT
IL-6, interleukin-6; R.A.R.E., Recordati Access, Resources, and Engagement.
What is SYLVANT?
SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. It is not known if SYLVANT is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Who should not receive SYLVANT?
Do not receive SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Patient Information leaflet for SYLVANT for a complete list of ingredients.
Before starting SYLVANT, tell your healthcare provider (HCP) about all of your medical conditions, including if you:
- have an infection. You should not receive SYLVANT if you have a severe infection.
- have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT.
- have or have had any stomach or bowel (intestine) problems, such as diverticulitis or ulcers. Tell your healthcare provider if you have pain in your stomach area.
- are pregnant or plan to become pregnant. It is not known if SYLVANT will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT and for 3 months after stopping treatment.
- are breastfeeding or plan to breastfeed. It is not known if SYLVANT passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT or breastfeed. You should not do both.Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SYLVANT?
SYLVANT may cause serious side effects, including:
- Infections. SYLVANT may lower your ability to fight infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection during treatment with SYLVANT.
- Infusion and allergic reactions. If you have an infusion or allergic reaction while receiving SYLVANT, your healthcare provider will stop your infusion and treat your reaction. If you have a severe infusion or allergic reaction, your healthcare provider may stop your treatment completely. Tell your healthcare provider or get medical help right away if you have any of these symptoms during or after your infusion of SYLVANT: back pain, chest pain or tightness, nausea and vomiting, flushing, redness, irregular heart beat (palpitations), trouble breathing, wheezing, dizziness or light-headedness, swelling of the lips, skin rash, headache, or itching.
- The most common side effects of SYLVANT include rash, itching, upper respiratory tract infection, swelling, weight gain, and increased blood level of uric acid.
These are not all the possible side effects of SYLVANT. Call your HCP for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.
SYLVANT® (siltuximab) for injection, for intravenous use, is available as 100 mg or 400 mg of lyophilized powder in a single-dose vial.
Please see full Prescribing Information, including Patient Information.
